Coherus Oncology, Inc. (CHRS) Earnings History
Net Loss14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Coherus Oncology, Inc. (CHRS) Earnings Overview
As of June 23, 2026, Coherus Oncology, Inc. (CHRS) reported trailing twelve-month net income of -$152M, reflecting -680.0% year-over-year growth. The company earned $-1.11 per diluted share over the past four quarters, with a net profit margin of -403.8%.
Looking at the long-term picture, CHRS's historical earnings data spans multiple years. The company achieved its highest annual net income of $132M in fiscal 2020.
Coherus Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), AMRX ($72M net income, 2.4% margin), HCM ($467M net income, 83.3% margin), CHRS has room to improve margins relative to the peer group. Compare CHRS vs PRGO →
CHRS Earnings vs Peers
Earnings metrics vs comparable public companies
CHRS Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$170M | -697.4% | -$180M | $-1.45 | -403.8% | -425.7% |
| 2024 | $29M | +112.0% | -$112M | $0.25 | 10.7% | -41.8% |
| 2023 | -$238M | +18.5% | -$203M | $-2.53 | -92.5% | -79.0% |
| 2022 | -$292M | -1.6% | -$257M | $-3.76 | -138.2% | -121.7% |
| 2021 | -$287M | -317.1% | -$264M | $-3.81 | -87.9% | -80.8% |
| 2020 | $132M | +47.2% | $156M | $1.62 | 27.8% | 32.9% |
| 2019 | $90M | +142.9% | $108M | $1.23 | 25.2% | 30.3% |
| 2018 | -$209M | +12.1% | -$204M | $-3.22 | -13453.7% | -13137.3% |
| 2017 | -$238M | -87.0% | -$232M | $-4.48 | -15306.6% | -14918.8% |
| 2016 | -$127M | +43.0% | -$116M | $-3.04 | -67.0% | -61.0% |
| 2015 | -$223M | -156.2% | -$219M | $-6.01 | -743.2% | -729.2% |
| 2014 | -$87M | -62.5% | -$65M | $-10.64 | -280.1% | -207.9% |
| 2013 | -$54M | -62.4% | -$36M | $-2.97 | -1949.7% | -1308.4% |
| 2012 | -$33M | - | -$39M | $-11.69 | -1738.7% | -2028.3% |
Download Data
Export CHRS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CHRS — Frequently Asked Questions
Quick answers to the most common questions about buying CHRS stock.
What is CHRS earnings per share (EPS)?
CHRS trailing twelve-month (TTM) diluted EPS is $-1.11, reflecting -680.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Coherus Oncology, Inc.'s net income?
Coherus Oncology, Inc. (CHRS) trailing twelve-month net income is $-152M as of 2025. Earnings declined -680.0% year-over-year.
Is CHRS profitable?
CHRS is not currently profitable on a TTM basis, reporting a net loss of $-152M. Net margin is -403.8%. Investors should monitor for a return to profitability.
What is CHRS's earnings growth rate?
CHRS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are CHRS's profit margins?
Coherus Oncology, Inc. net profit margin is -403.8%, operating margin is -425.7%, and gross margin is +57.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is -279.1%.
Is CHRS growing earnings?
CHRS earnings are declining — EPS fell -680.0% year-over-year. TTM net income dropped to $-152M. This contrasts with the 5-year CAGR of N/A.
What was CHRS's best earnings year?
Coherus Oncology, Inc.'s highest annual net income on record is $132M, achieved in fiscal year 2020. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were CHRS's earnings last quarter?
CHRS's most recent reported quarter was Q1 2026. Net income was $-38M with diluted EPS of $-0.28. For a full breakdown of all quarters, see the quarterly earnings table on this page.